Table 9. Comparative median survival times of patients by tumour characteristics and metastasis.
| Variable, frequency(N) | Median survival time (months) 95%CI | Log rank test | p value |
|---|---|---|---|
|
Tumour site, N = 378 Right Left Bilateral |
47.0 (35.0–60.0) 41.0 (33.0–48.0) 17.0 (13.0–50.0) |
6.42 |
0.0403 |
|
Clinical tumour size (cm), N = 182 <2 2–5 >5 |
18.0 (18.0–) - 38.0 (30.0–48.0) |
10.85 |
0.0044 |
|
Stage of presentation, N = 353 Early stage Late stage |
- 36.0 (31.0–43.0 |
21.05 |
<0.001 |
|
Bone metastasis, N = 378 No Yes |
43.0 (35.0–48.0) 39.0 (26.0–60.0) |
0.72 |
0.3974 |
|
Liver metastasis, N = 378 No Yes |
45.0 (39.0–53.0) 20.0 (16.0–33.0) |
10.05 |
0.0015 |
|
Lung metastasis, N = 378 No Yes |
47.0 (40.0–55.0) 30.0 (22.0–36.0) |
12.09 |
0.0005 |
|
Spine, N = 378 No Yes |
41.0 (34.0–48.0) 43.0 (21.0–60.0) |
0.68 |
0.4083 |
|
Total metastasis, N = 378 No Yes |
51.0 (41.0–60.0) 30.0 (24.0–36.0) |
18.05 |
<0.001 |
|
Clinical axillary lymph nodes metastasis, N = 359 Non-palpable Palpable ipsilateral Palpable contra lateral |
-(43.0–) 34.0 (29.0–41.0) 23.0 (9.0–48.0) |
22.80 |
<0.001 |
|
Supraclavicular lymph node, N = 353 No Yes |
41.0 (34.0–49.0) 24.0 (18.0–40.0) |
8.62 |
0.0033 |